Martin Madaus Elected to Haemonetics Board of Directors

PR Newswire··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Haemonetics Corporation has elected Martin Madaus to its Board of Directors, effective July 24, 2026. Dr. Madaus brings more than 30 years of leadership experience in diagnostics and life sciences tools, currently serving as Senior Operating Executive at The Carlyle Group. He previously led Ortho Clinical Diagnostics as Chairman and CEO, and Millipore Corporation as Chairman, President and CEO, where he oversaw its acquisition by Merck KGaA. He also serves as Chair of Repligen Corporation and as a board member of Azenta, Inc. Haemonetics Chair Ellen Zane stated that his operational and strategic expertise will support the company's growth and long-term value creation.

Impact on assets 7

Biotech & Genomic Medicine▲ · 5 stocks
Haemonetics Corporation
HAE
▲ PositiveCapitalrelevance

Election of experienced board member with operational and strategic expertise expected to support growth and value creation.

Financials▲ · 1 stocks
Critical Materials & Supply Chain▲ · 1 stocks
© 2026 MarketIVNews